ReviewNutrients2025
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.Nutrition & metabolism · 2026Article
- Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis of Randomized Controlled Trials.Endocrinology, diabetes & metabolism · 2026Review
- From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2026Review
- Impact of underlying liver etiology on post-hepatectomy survival outcomes in hepatocellular carcinoma patients.Translational cancer research · 2025Article
- MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.Hepatic medicine : evidence and research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide. Its incidence has been increasing rapidly, alongside the growing epidemics of type 2 diabetes mellitus and overweight/obesity. Global population age has also been increasing in parallel, and predictions indicate there will be more than 2 billion persons aged over 65 by the year 2050. The interplay between MASLD and other health conditions of older persons has been a focus of recent research. In this narrative review, we aim to describe its prevalence; clinical and sociodemographic associations; and outcomes for older persons, all of which are of significant importance when considering public health messaging as well as screening and counselling individual older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.